Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 197 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intraocular Pressure (IOP) Clear all
Completed Phase 2 Interventional

A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

NCT05133518
View directory record Official record
Conditions
Cataract
Interventions
MELT-300, Midazolam alone, Ketamine alone, Placebo
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Rancho Cordova, California • Jacksonville, Florida • West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 30, 2026, 4:56 PM EDT
Terminated Not applicable Interventional

Safety and Effectiveness of the Hydrus Microstent

NCT05198297
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Bentonville, Arkansas • Zephyrhills, Florida • Fraser, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 30, 2026, 4:56 PM EDT
Not listed Not applicable Interventional

Effects of a Single Osteopathic Manipulative Treatment (OMT) on Intraocular Pressure (IOP) Reduction

NCT03590249
View directory record Official record
Conditions
Glaucoma
Interventions
Osteopathic Manipulative Treatment
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 30, 2026, 4:56 PM EDT
Recruiting Not applicable Interventional

Glaucoma Laser Assessment of Stability and Sustainability

NCT06963684
View directory record Official record
Conditions
Glaucoma
Interventions
Dual-Treatment Direct Selective Laser Trabeculoplasty (DSLT)
Device
Lead sponsor
Twin Cities Eye Consultants
Other
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Coon Rapids, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Phase 3 Interventional

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

NCT07082816
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
30
States / cities
Dothan, Alabama • Phoenix, Arizona • Garden Grove, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

AR-12286 in Combination With Latanoprost

NCT01302249
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
15
States / cities
New Haven, Connecticut • Roswell, Georgia • Shawnee Mission, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 30, 2026, 4:56 PM EDT
Completed No phase listed Observational

Intraocular Pressure During Robotic Assisted Laparoscopic Procedures Utilizing Steep Trendelenburg Positioning

NCT01261871
View directory record Official record
Conditions
Ocular Hypertension
Interventions
Not listed
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

SYL040012, Treatment for Open Angle Glaucoma

NCT02250612
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate
Drug
Lead sponsor
Sylentis, S.A.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Artesia, California • Petaluma, California • Morrow, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 30, 2026, 4:56 PM EDT
Not listed Phase 4 Interventional

The Effect of Education on Patient Compliance

NCT00376974
View directory record Official record
Conditions
Glaucoma
Interventions
American Academy of Ophthalmology Glaucoma Educational Tape
Behavioral
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
40 Years to 90 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2006 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

NCT00315640
View directory record Official record
Conditions
Eye Diseases
Interventions
Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Suspension Depot, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
5
States / cities
Jacksonville, Florida • Miami, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Not applicable Interventional

SOLX Gold Shunt for Refractory Glaucoma

NCT01282346
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open Angle
Interventions
SOLX Gold Shunt
Device
Lead sponsor
SOLX, Inc.
Industry
Eligibility
21 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Springdale, Arkansas • Irvine, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 30, 2026, 4:56 PM EDT
Completed No phase listed Interventional Results available

Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure

NCT04962009
View directory record Official record
Conditions
Elevated Intraocular Pressure (IOP)
Interventions
Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug
Combination Product
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

NCT04521140
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

NCT01474135
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.25% AR-12286 / 0.004% travoprost, 0.5% AR-12286, 0.004% travoprost, 0.004% Travoprost
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Inglewood, California • Newport Beach, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure

NCT02448043
View directory record Official record
Conditions
Nail Growth Cessation, Intraocular Pressure
Interventions
Bimatoprost 0.01%, Placebo: saline
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Caffeinated Coffee on Intraocular Pressure

NCT01364207
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Caffeinated Coffee, Decaffeinated Coffee
Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Safety and Feasibility of the ELIOS System in POAG Patients

NCT05999006
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
ELIOS Procedure
Device
Lead sponsor
Elios Vision, Inc.
Industry
Eligibility
45 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Glendale, Arizona • Rock Island, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 30, 2026, 4:56 PM EDT
Recruiting No phase listed Observational

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients

NCT07076303
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Glaucoma, Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
Direct Selective Laser Trabuloplasty
Device
Lead sponsor
Brian Shafer
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2026
U.S. locations
1
States / cities
Plymouth Meeting, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 30, 2026, 4:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

IOP Lowering Effects of Topical Anesthetics Used Frequently in the Ophthalmology Clinic

NCT01254149
View directory record Official record
Conditions
Normal Tension Glaucoma
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Brimonidine

NCT03959176
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Brimonidine, Tropicamide, Phenylephrine Ophthalmic Product
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Results available

AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure

NCT01484951
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 1% and timolol 0.5% fixed combination eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
20 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Sep 30, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT01687426
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
Brimonidine Tartrate 0.025%, Vehicle
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Winchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Sep 30, 2026, 4:56 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles

NCT02142114
View directory record Official record
Conditions
Pain
Interventions
Eye injection by 30 or 32 gauge needle
Device
Lead sponsor
Retina Health Center
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Sep 30, 2026, 4:56 PM EDT
Not listed Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

NCT06383273
View directory record Official record
Conditions
Cataract
Interventions
MELT-300 sublingual tablet, Midalozam sublingual tablet, Placebo sublingual tablet
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Chico, California • Grand Junction, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Sep 30, 2026, 4:56 PM EDT